Eisai to begin administering new Alzheimer’s drug in China, expects significant growth in 2025

On February 4, the major pharmaceutical company Eisai aims to start giving lecanemab, a new Alzheimer’s disease drug developed jointly with the US company Biogen, to 1,500 people in China by the end of the year. In this photo, a scientist looks at a brain scan at a university hospital in Geneva, Switzerland. The picture was taken in June last year (2024 Reuters/Denis Balibouse)

[シカゴ/上海 ４日 ロイター] – Pharmaceutical giant Eisai (4523.T), opens new tab plans to start giving lecanemab, a new Alzheimer’s disease drug jointly developed with U.S. Biogen (BIIB.O), opens new tab, to 1,500 people in China by the end of the year. want to be In addition, significant growth is expected in 2025 due to changes in diagnostic methods. a spokesman told Reuters.

As diagnosis can be made using a more convenient blood test, use is expected to increase among the estimated 17 million patients with early-stage disease.

China approved lecanemab last month.

The new drug is already on sale in the United States and Japan. Under review in Europe.

Eisai expects to start using the new drug in China by September, and expects to administer it to a total of 1,500 people by March 2025.

Sales of new drugs could increase significantly in 2025 with the introduction of blood tests, which are easier to diagnose than diagnostic methods that require access to specialists.

Eli Lilly ( LLY.N ), opening a new tab, which developed an Alzheimer’s disease-like drug, donanemab, told Reuters it had applied for approval in China.

* For related information, see the “Related Content” menu on the right side of the screen.

Our Code of Conduct: Thomson Reuters “Principles of Trust”, opens a new tab

#Eisai #aims #administer #lecanemab #people #China #expected #increase #significantly #Reuters